Paradigm BioCapital Advisors LP Discloses 3.3% Stake in Erasca, Inc. (ERAS)

Paradigm BioCapital Advisors LP, along with its affiliates, filed a Schedule 13G/A on May 15, 2026, disclosing a 3.3% ownership stake in Erasca, Inc. (ERAS). The reporting group, which includes Paradigm BioCapital Advisors GP LLC, Senai Asefaw, M.D., and Paradigm BioCapital International Fund Ltd., reported aggregate beneficial ownership of 10,392,702 shares of common stock. Specifically, the International Fund directly holds 9,157,687 shares (2.9%), while the remaining shares are held through separately managed accounts. This filing marks an increase from a previously reported 0% position, with the valuation of the current holding estimated at approximately $106.3 million. The reporting persons have certified that these shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. The percentages are based on 310,806,888 shares of common stock outstanding as of March 31, 2026.